Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson
Raymond and Nina describe their outcomes from stem cell therapy by Dr Harry Adelson for their various arthritic pains http://www.docereclinics.com.
By: Harry Adelson, N.D.
Read more here:
Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson - Video
The great promise of stem cells may finally be getting close for multiple sclerosis patients.
Stem cells, which have the power to transform into other types of cells, have been much anticipated for more than a decade as a way to treat or even cure diseases like MS, Parkinson's, blindness, and spinal cord injuries. But it's taken time to turn that promise into a workable reality.
Two new studies, both published in the journal Stem Cell Reports, suggest that researchers are getting close.
"We haven't landed on the moon yet, but we've tested in the rockets," said Jeanne Loring, author of one of the studies and a professor and director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla, Calif.
Her study found that a certain type of stem cell, injected once into the spinal cords of mice with an MS-like condition, could dramatically improve the animals for at least six months.
The mice's immune systems almost immediately rejected and destroyed the cells, known as human embryonic stem cell-derived neural precursor cells. But the cells seemed to trigger a long-lasting benefit, dampening inflammation to slow the disease's progression, and repairing the damaged sheathing around nerve cells that is the hallmark of MS, according to Thomas Lane, a neural immunologist at the University of Utah who helped lead the research.
The other study, led by Robert Lanza, chief scientific officer of Advanced Cell Technology, a Massachusetts-based biotech, showed that mice with an MS-like disease could be restored to near normal by injecting them with a different type of stem cell. When injected, these cells ?? mesenchymal stem cells derived from human embryonic stem cells ?? were able to home in on damaged cells in the nervous system, even crossing the blood-brain barrier, Lanza said.
They not only reduced the symptoms of the disease, but prevented more damage to nerve cells, he said.
The two studies together "speak to the changing role of stem cells and their potential as treatment strategies for MS," said Tim Coetzee with the National Multiple Sclerosis Society, an advocacy group. The idea of using stem cells in MS has been around for a while, but these two studies overcome some of the challenges of finding a therapy that can be consistent and effective for many people.
"They set the stage quite impressively for potential work in humans," he said, with clinical trials likely within the next few years.
Here is the original post:
New stem cells may help in battling multiple sclerosis
PUBLIC RELEASE DATE:
5-Jun-2014
Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair
Putnam Valley, NY. (June 5, 2014) A study by a Korean team of neuroscientists has concluded that when mesenchymal stem cells (MSCs; multipotent structural stem cells capable of differentiation into a variety of cell types) are transplanted into the brains of mice modeled with Alzheimer's disease (AD), the cells stimulate neural cell growth and repair in the hippocampus, a key brain area damaged by AD. The finding could lead to improved AD therapies.
The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT1059Oh.
Neuroscientists know that Alzheimer's disease is caused by the presence of amyloid-B (AB) "plaques" and "tangles" in the brain's network of neurons. Recently, a protein signaling pathway called "Wnt" (Wingless-type mouse mammary tumor virus (MMTV) related integration site family) which plays a role in embryonic development as well as the development of some diseases, such as cancer, has been linked to Alzheimer's disease. Researchers speculate that an interruption in the Wnt pathway signaling process caused by the AB plaque buildup may have an impact on potential brain cell renewal processes, called neurogenesis. Evidence has indicated that the Wnt signaling pathway plays an important role in the pathogenesis of AD.
This study was carried out to determine if MSCs benefitted neurogenesis in the hippocampus by "modulating" the Wnt pathway in such a way that that the MSCs are able to differentiate into neuronal progenitor cells (NPCs) that could help rebuild the affected areas of the brain.
"Recent studies have shown that MSCs express various proteins related to the Wnt pathway," said study co-author Dr. Phil Hyu Lee, Department of Neurology, Yonsei University College of Medicine in Seoul, South Korea. "It has also been determined that MSCs derived from bone marrow produce biologically active Wnt proteins that may counteract the negative influence of AB on neuronic activity."
The authors report that MSC treatment of AD in cellular and animal models significantly increased hippocampal neurogenesis and enhanced neuronal differentiation of NPCs.
"Our data suggest that the modulation of adult neurogenesis and neuronal differentiation to repair the damaged AD brain using MSCs could have a significant impact on future strategies for AD treatment," the researchers concluded.
Read more:
Stem cells found to play restorative role when affecting brain signaling process
New York, NY (PRWEB) June 04, 2014
The Animal Medical Center of New York is offering stem cell therapy provided through Vet-Stem and long-term management in a clinical trial for qualifying cats with chronic kidney disease (CKD). The ultimate goal of this study is to investigate the use of stem cells (obtained from the patients own fat) in aiding the enhancement of renal (kidney) function by their regenerative capabilities, with the goal of improving survival in cats with CKD.
Currently there are no therapeutic options for cats with CKD other than renal transplantation, which is not typically an option for most owners. Most efforts aim at improving uremic signs with food, dietary supplements, and antacids, but there are no current methods for improving function of the kidney directly. CKD is the leading cause of death in older cats, and 35% of cats will develop CKD at some point.
Since renal failure is so common in cats and renal cell death is the ultimate result, improving the health and environment of the cells that remain could improve the overall function of the kidneys and ultimately improve the survival times and quality of life in patients. The aim is to use the cats own adipose (fat) derived stem cells to improve renal function directly, as stem cells are thought to improve, repair, and aid in the growth of damaged tissue.
The potential health benefits of using stem cells to combat CKD include renal regeneration, anti-fibrotic effects, a decrease in proteinuria (also called urine albumin or an abnormal amount of protein in the urine), and an improvement in the Glomerular Filtration Rate (GFR used to help measure kidney function). AMC is offering free fat collection, isolation of the stem cells from the fat, and intra-arterial injection for qualifying cats, as well as free follow-up for three years. Qualifying cats must be diagnosed with IRIS Stage 3 CKD that have had no other experimental therapies. Potential candidates must undergo a full workup and have no history of urinary tract stone disease or the presence of other concurrent, unrelated disease.
Allyson Berent, DVM, DACVIM and Catherine E. Langston, DVM, DACVIM will be leading the three year study, and invite owners with a cat that has been diagnosed with CKD to call 212.329.8763 for more information on qualifying for the clinic trial. To learn more about the study go to http://www.amcny.org/clinicaltrials. To watch a short special interest film about one cats success go to http://www.vet-stem.com/pr_detail.php?id=49.
The Animal Medical Center in New York City is a federally recognized 501(c)(3) non-profit veterinary center that has been a national leader in animal care since 1910. As an academic veterinary hospital, The AMC promotes the health and well-being of companion animals through advanced treatment, research and education. Stem Cell Therapy through Vet-Stem has been offered at AMC since 2008 to treat pain associated with chronic osteoarthritis. To find out more about AMC and their stem cell therapy services for osteoarthritis go to http://www.amcny.org/surgery/neurosurgery/stem-cell-therapy.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Go here to see the original:
Animal Medical Center of New York Seeks Candidates for Clinical Trial for Cats with Chronic Kidney Disease to Receive ...
Americans Support Stem Cell Research
Support
Oppose
Research!America supports federal funding for stem cell research on both adult and embryonic cell lines and works to promote and protect stem cell research at the state and federal levels. We work closely with our partners, the Stem Cell Action Coalition and the Coalition for Advancing Medical Research, to advocate on behalf of stem cell research.
Former President George W. Bush permitted federal funding for embryonic stem cell research (ESCR) only if the stem cells were obtained from a limited number of previously existing stem cell lines. In 2009, President Barack Obama issued an executive order expanding the opportunities for federally funded ESCR by permitting the use of embryonic stem cells other than those obtained from the previously designated stem cell lines. However, legislation to protect this expansion in research opportunities has never been signed into law, which gives future administrations the discretion to curtail or eliminate federally funded stem cell research.
Rep. Diana DeGette (D-CO) is currently sponsoring H.R. 2376, also known as the Stem Cell Research Advancement Act, which would codify the stem cell rules established under President Obamas executive order, preventing future administrations from unilaterally restricting or eliminating federal funding for stem cell research. The legislation would permit funding for research on stem cells derived from embryos produced, but ultimately not used, for in vitro fertilization. The bill currently has 28 cosponsors and no Senate equivalent.
On August 23, 2012, in a decision favorable to proponents of embryonic stem cell research, the U.S. Court of Appeals for the D.C. Circuit upheld a lower court ruling dismissing a lawsuit that challenged the Obama administrations expansion of federal funding for embryonic stem cell research.
The Supreme Court declined to hear the appeal in an announcement on January 7, 2013. The announcement allows the decision of the appeals court to stand.
Here is the original post:
Stem Cell Research - Research!America
GOLTRY, Okla. Armed with stem cells, a Goltry area woman will be heading to Milwaukee next week to join in her brothers cancer fight.
Jeni Sumner was the only match among family members tested to donate stem cells to her younger brother, Ed Dee.
To me, Ive been given a gift. I know everybodys congratulating me and saying its a wonderful thing, and not taking it away from that, but I think Ive been given just a tremendous gift, Sumner said.
Along with helping her brother, Sumner is trying to encourage others to join the bone marrow donor registry.
I think a lot of people are afraid to join because they might get called, because they dont know what its like to be a donor, she said. I want more people to become aware of what its actually like to be a donor.
Sumner set up a Facebook page It Doesnt Hurt - To Save a Life to chronicle everything she will go through, as a donor, during the procedure.
Its an unknown for me, but its nothing compared to what my brothers going through, she said. I know the feeling that I got when I got the call from the doctor saying that I was his donor. The relief and the joy that I felt that our family doesnt have to look anymore. If anything happens, were covered because we have a donor, we have a match. The feeling that I got was incredible, she said.
Dee, of Milwaukee, Wis., was diagnosed with acute myelogenous leukemia last year. Sumner said he went into remission last October.
Unfortunately, the cancer came back. This type of leukemia is a very dangerous and aggressive form. He, every couple of weeks, would go in for a blood test and this March he was informed that his leukemia had come back, she said. His doctors feel that a stem cell transplant would be the best for him, at this time.
Following the return of the cancer, Dee went through five days of rigorous chemotherapy to put him back into remission. He recently finished a lower dose session of chemo, Sumner said.
Visit link:
Using stem cells, woman joins brothers cancer fight
1 hour ago Haruko Obokata (L), a researcher at Japan's Riken Institute, bows as she apologises at a press conference in Osaka on April 9, 2014
A Japanese stem cell scientist accused of fabricating research has agreed to retract papers published in the respected journal Nature, an official said Wednesday.
Haruko Obokata, 30, would withdraw two papers at the centre of the controversy, according to a spokeswoman for Riken, the respected research institute that sponsored the study, marking a steep fall from grace for the young researcher.
"We confirmed that she agreed to retract both articles," the spokeswoman said.
She added that Riken was "still discussing" a retraction with co-author Charles Vacanti of Harvard University.
Obokata was feted after unveiling findings that appeared to show a straightforward way to re-programme adult cells to become stem cellsprecursors that are capable of developing into any other cell in the human body.
Identifying a readily manufacturable supply of stem cells could one day help meet a need for transplant tissues, or even whole organs, meaning that any advance in the field is usually met with excitement in the scientific community.
The study was front-page news in Japan, but within weeks of Obokata's paper on so-called Stimulus-Triggered Acquisition of Pluripotency (STAP) cells being published, questions began to emerge, with fellow scientists saying they could not replicate her results.
Riken had urged the scientist to withdraw her two papers, after concluding that she fabricated at least some of the data.
Explore further: Japan scientist to retract one stem cell paper
Excerpt from:
Japanese scientist to retract stem cell papers
stem cell therapy-treatment for adhd by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for Global Developmental Delay with Attention Deficit Hyperactivity Disorder predominantly Hyperactivity Disorder by dr alok...
By: Neurogen Brain and Spine Institute
Read the original:
stem cell therapy-treatment for adhd by dr alok sharma, mumbai, india - Video
Boston, MA (PRWEB) June 03, 2014
Today, Dr. James L. Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC) described a new technology for identification of new drug candidates that are toxic to adult stem cell cells in the human body. The new AlphaSTEM technology is the first of its kind to address a long-standing unmet need in the pharmaceutical industry.
Dr. Sherley presented the AlphaSTEM technology at the 7th Annual Massachusetts Life Sciences Innovation Day (MALSI Day 2014; http://www.mattcenter.org/malsi-day-2014/home.html) at the Harvard Club of Boston. ASCTC is one of a select number of start-up companies invited to present posters on their newest innovative biotechnologies at the all day event, which features the best and brightest life sciences innovations of the year.
Just as adult stem cells are crucial for life and normal organ function, their safety is crucial for successful treatment with new drugs. Even if a new drug has high activity against a disease or disorder; it will not be an effective treatment, if it is also too toxic to adult stem cells.
Adult stem cells are found in all renewing tissues and organs of the human body, like hair, skin, liver, and even the brain. They are responsible for replacing old mature tissue cells with new young cells. They are also essential cells for repairing injured tissues and wounds.
Some drugs are known to harm adult stem cells. Examples of these are many cancer drugs. Cancer drugs are often administered at the highest doses at which patients can tolerate the adverse effects of the drugs on adult stem cells. ASCTCs AlphaSTEM technology could accelerate discovery of better cancer drugs with less adult stem cell toxicity.
The major application proposed for the new AlphaSTEM technology is use by pharmaceutical companies to identify adult stem cell-toxic drugs before initiating clinical trials with them or entering the marketplace. Drug failure in clinical trials due to safety concerns is a major unrecovered cost of drug development. Chronic adult stem cell toxicity that now may go undetected until after marketing can result in tragic deaths for patients and catastrophic injury liabilities for the responsible drug companies. The Merck drug Vioxx is an example of such an unfortunate mishap.
The problem faced by the Food and Drug Administration (FDA) and the pharmaceutical industry is how to monitor drug effects on adult stem cells, when the cells are difficult to identify, isolate, produce, and count. The solution presented by ASCTC was a computer simulation approach based on the universal tissue cell production properties of adult stem cells.
ASCTC partnered with AlphaSTAR Corporation, a leading global provider of simulation technologies, to develop the AlphaSTEM software program that can simulate the culture multiplication of adult tissue stem cells found in any human tissue. AlphaSTEM technology not only has the power to detect drug toxicity against adult stem cells, but also against other specialized types of tissue cells specifically.
Director Sherley predicted that the introduction of AlphaSTEM technology into the pharmaceutical industry would have many immediate benefits. With relatively inexpensive detection of drugs destined to fail in expensive clinical trials, the new technology could save billions of currently wasted dollars, reducing overall drug development costs in the U.S. by as much as 20%. These savings could accelerate the rate of arrival of new effective drugs to patients by a comparable reduction in time. AlphaSTEM technology may also reduce the occurrence of drugs thought safe, but which actual have a lurking toxicity that emerges as lethal to some patients with wider and longer use.
Read more from the original source:
The Adult Stem Cell Technology Center, LLC Announces New Technology for Preventing Catastrophic Adult Stem Cell ...
Dr. Mark Penn, founder and CMO of Juventas Therapeutics
While the optimal treatment for heart failure was provided to a group of patients, they were still having symptoms. However when a new drug therapy based in regenerative medicine was given to these patients they showed clinically meaningful improvements in end systolic volumes, end diastolic volumes, ejection fraction and NTproBNP levels.
The drug, produced by Cleveland, Ohio-based Juventas Therapeutics, called JVS-100, is a non-viral gene therapy that expresses SDF-1 and promotes endogenous stem cell repair of the heart in patients with severe heart failure.
"What was remarkable about the improvement is that this drug was given to patients who had heart failures stemming from heart attacks that occurred - on average- about eleven years ago," said Dr. Mark Penn, founder and CMO of Juventas Therapeutics, and director of Cardiovascular Research at Summa Health System in Akron, Ohio.
Penn presented phase II clinical data last month at the European Society of Cardiology- Heart Failure Congress in Athens, Greece.
The field of regenerative medicine, which is the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function, has come a long way. Penn explained that 14 years ago that stem cell based repairs lacked molecular signals that orchestrated the repairs. "Doing research we asked what drives stem cell repair? We saw that newly injured tissue was sending some signal to ask for it to be repaired. And in 2000 we discovered SDF-1 could aid that signal. Now our theory is validated that the gene therapy is a key factor for recruiting stem cells to the site for any injured tissue."
The therapy showed an 80% chance of a significant decrease in mortality for high risk heart failure patients.
With this success, Penn hopes to start next summer of 2015 on a larger trial of 300-400 patients. When that trial is initiated the company will have to move from manufacturing the drug for clinic studies to a commercial scale. Once the drug has regulatory approval the company will decide where to manufacture.
When asked about the reason for the success of the company, Penn says that "the company has always been driven by data. We had no preconceived ideas that this should work. We designed good trials, looked at the data and that told us where to go."
With regard to the financial side of the business, the company has worked with venture investors. And they have formed partnerships. The company has on-going collaborative research programs with Cleveland Clinic, Center for Stem Cell & Regenerative Medicine, Global Cardiovascular Innovation Center and Summa Health System.
Follow this link:
New Drug-Based Approach to Regenerative Medicine for Heart Failure